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%   Percentage 
Kg.  Kilogram 
gm.   Gram 
mg.   Milligram 
μg.   Micro gram 
ml.   Milliliter 
cm.   Centimeter 
mm.   Millimeter 
nm.   Nanometer 
w/w   Weight by weight 
w/v   Weight by volume 
avg.   Average 
hrs.   Hours 
pH.   Hydrogen ion concentration 
oC   Degree centigrade 
RH.   Relative Humidity 
HCl   Hydrochloric acid 
RPM.   Revolution per minute 
Abs.   Absorbance 
Conc.   Concentration 
Fig.   Figure 
UV-VIS  Ultra violet and visible spectroscopy 
FTIR   Fourier Transform Infrared spectroscopy 
C.I   Compressibility Index 
CR   Cumulative Release 
SR   Sustained Release 
USP               United State Pharmacopoeia 
BP                 British Pharmacopoeia 
R2                           Regression coefficient 
 ABSTRACT 
The sustained release drug delivery is the drug delivery system that achieves the 
release of drug in the proper amount at regular time interval over an extended period of 
time and is time independent. The aim of present work was to formulate and evaluate 
sustained release tablets of Paliperidone using natural gums in order to reduce the 
various side effects associated with Paliperidone as well as to overcome the 
manufacturing difficulties. For formulating sustained release drug delivery system, 
natural hydrophilic polymers are used.  Natural binders provides the tablet formulations 
with good hardness and friability. These binders prolongs  the dissolution rate of some 
slightly soluble drugs and can be chosen as good candidate for sustained release. 
Tablets were prepared by direct compression method using different drug-polymer 
concentration. FT-IR study revealed that there was no chemical interaction between the 
drug and polymers used. Pre-compression and post-compression parameters complied 
with Pharmacopoeial limit for the tablets. Four different gums (Cassia roxburghii, 
Tamarindus indica , Azadirachta indica and Manihot esculenta) were used in 3 
different concentrations (35%, 50%, 75%) and was compared with the standard rate 
retardant polymer HPMC. The in vitro release study was performed and the results 
indicated that the formulation F12 (Neem gum 75%) was found to be the  optimized 
formulation which can extend  the release up to a period of 24 hours. The kinetic release 
data showed that the optimized formulation followed zero order kinetics. From the 
stability studies it was clear that the formulation was stable after 3 months at accelerated 
condition of 400C±20C/75% RH±5% in a stability chamber. 
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1. INTRODUCTION 
Oral drug delivery has been known for decades as the most widely utilised 
route of administration among all the routes that have been explored for the systemic 
delivery of drugs via various pharmaceutical products of different dosage forms. The 
popularity of this route may be due to its ease of administration and also due to the 
belief that by oral administration the drugs are well absorbed as the food stuffs that 
are ingested daily1. 
Among all the forms that are administered orally; solid oral dosage forms ie, 
tablets and capsules are the most preferred class of dosage forms. Tablet is defined as 
a compressed solid dosage form containing medicaments with or without excipients. 
According to the Indian Pharmacopoeia Pharmaceutical tablets are solid, flat or 
biconvex dishes, unit dosage form, prepared by compressing a drugs or a mixture of 
drugs, with or without diluents. Depending on the mode of administration and the 
amount of medicinal substances, shape, size and weight of the formulations will get 
varied. It is the most popular dosage form and 70% of the total medicines are 
dispensed in the form of tablet. 
Recent advancement in the pharmaceutical field has resulted in the 
development of new technologies for drug delivery. The newly developed techniques 
are capable of controlling the rate of drug delivery, sustaining the duration of 
therapeutic activity, and/or targeting the delivery of drug to a tissue. The objectives in 
designing sustained or controlled delivery systems are: 
 To reduce the frequency of the dosing. 
 To increase effectiveness of the drug by localization at the site of action. 
 Reducing the dose required or providing uniform drug delivery. 
 To ensure safety and to improve efficacy of drugs as well as patient 
compliance. 
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Fig 1: Plasma level concentration of CR, SR and  
conventional release. 
 
Normally, hydrophilic polymers are preferred in formulating oral-controlled 
release tablets. When the dissolution medium penetrates in to the dosage form, the 
polymer material swells and by diffusion, the drug molecules comes out of the system 
at a determined rate by the nature, composition of polymer and type of formulation. 
The natural gums are selected since they are cheaper, bio-compactable and less toxic 
as compared to synthetic gums. Natural products are used as disintegrant, suspending 
agent, emulsifying agent and as binders used in formulating immediate and sustained 
release formulations.  
The sustained release tablets are prepared by direct compression technique. 
HPMC, Cassia roxburghii, Tamarindus indica, Azadirachta indica and Manihot 
esculenta are the natural polymers used in various concentrations for formulating 
sustained release tablets.   
Advantages of Conventional Oral Dosage Forms2 
 High convenience. 
 High level of patient acceptability. 
 Good physical and chemical stability  
 Convenience of self administration. 
 Self administration can be done. 
 Large scale production can be done easily. 
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 Easy to package and shipping. 
 Sustained release products can be formulated by enteric coating. 
 
Disadvantages of Conventional Oral Dosage Forms2                                                     
 Poor patient compliance. 
 Fluctuation in blood level for small therapeutic index drugs. 
 Chances for gastro intestinal irritant effects is high                               
(Eg:- Aspirin)  
 Difficult in administering to children, bed ridden and unconscious 
patients. 
 Some drugs cannot be compressed into tablets.    
Different Types of Tablets1 
A) Oral Tablets for Ingestion 
 Standard compressed tablets 
 Multiple compressed tablets 
a. Layered tablets 
b. Compression coated tablets 
c. Inlay tablets 
 Modified release tablets 
 Delayed action tablets 
 Targeted tablets 
a. Floating tablets 
b. Colon targeted tablets 
 Chewable tablets 
B) Tablets Used in the Oral Cavity 
 Buccal tablets 
 Sublingual tablets 
 Troches and lozenges 
 Dental cones 
C) Tablets Administered by Other Routes 
 Implantation tablets 
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 Vaginal tablets 
D) Tablets Used to Prepare Solution 
 Effervescent tablets 
 Dispersible tablets 
 Hypodermic tablets  
 Tablet triturates 
Sustained Release Drug Delivery System2 
The sustained release drug delivery system is the drug delivery system that 
achieves the release of drug over an extended time period and is time independent. 
For formulating sustained release drug delivery system, hydrophilic polymers are 
used. An ideal system should deliver proper amount of drug at regular time interval at 
the site of action and should be in the therapeutic range.  
Most preferred method for manufacturing sustained release drug delivery 
system is by direct compression method. Mostly hydrophilic polymers are used to 
formulate these tablets. The polymers used are HPMC, Cassia roxburghii, Tamarind 
powder, Neem powder and Tapioca starch. These polymers along with drug and other 
excipients are used in formulating an ideal sustained release formulation. 
Table 1: Parameters for drug release and drug delivery3 
 
 
 
 
 
 
 
 
PARAMETERS PREFERRED VALUE 
Molecular weight < 1000 
Solubility > 0.1 μg /ml for pH 1 to pH 7.8 
Apparent partition coefficient High 
Absorption mechanism Diffusion 
General absorbability From all GI segments 
Release Should not be influenced by pH and 
enzymes 
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Characteristics of Drug to be Used in Sustained Release Drug     Delivery 
System4,5 
 For shorter half-life drugs. 
 For drugs that are absorbed throughout the GIT. 
 For drugs having good solubility profile. 
 For smaller dose drugs. 
Advantages of Sustained Release Tablets6 
 Avoid patient compliance. 
 Low amount of drug is employed. 
 Eliminate local or systemic side effects. 
 Minimise drug accumulation. 
 Economy. 
 Improved efficiency in treatment. 
Disadvantages of Sustained Release Tablets6 
 Dose dumping. 
 Limited choice of selecting desired dose in a unit dosage form. 
 Poor in vitro-in vivo correlation. 
Classification of Sustained Release Tablets7 
Based on the mechanism of release of the drug from the polymer, the 
sustained release tablets are classified into 
A) Diffusion controlled systems. 
1) Matrix devices or systems. 
a. Hydrophobic matrix system.  
b. Hydrophilic matrix system. 
c. Reservoir matrix system. 
d. Semisolid matrix system. 
2) Reservoir devices or systems. 
Introduction                                                                                       
 
Dept of Pharmaceutics, KMCH College of Pharmacy Page 6 
 
B) Dissolution controlled systems. 
1) Matrix dissolution controlled systems. 
2) Encapsulation dissolution controlled systems. 
3) Diffusion and dissolution controlled systems. 
C) Osmotic controlled systems 
1) Osmotic delivery systems for solids. 
a) Type1: Single compartment 
b) Type2: Multiple compartments 
2) Osmotic delivery systems for liquids        
D) Bio-degradable polymeric drug delivery system 
1) Micro particles 
2) Nano particles 
3) Implants 
 
DIFFUSION CONTROLLED RELEASE SYSTEMS         
In diffusion controlled drug delivery system the dissolved drug diffuses through 
the polymeric barrier which act as the rate limiting membrane. In this  the release rate 
does not follow zero order, as the path length for diffusion increases with time as the 
insoluble matrix gradually get depleted of drug diffusion of a drug molecule through a 
polymeric membrane. This is the basis of controlled drug delivery system. The 
diffusion controlled devices are formulated either by encapsulating the drug particle 
in a polymeric membrane or by dispersing the drug in a polymeric matrix. 
In the case of reservoir type diffusion controlled devices, the rate of drug 
released (dm/dt) can be calculated by following equation 
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dm/dt = ADKC/l 
               
where, 
A = Area 
D = Diffusion coefficient 
K = Partition coefficient of the drug between the drug core  
and the membrane 
l  = Diffusion path length 
C = Concentration difference across the membrane 
 
MATRIX DEVICES OR SYSTEMS 
In this, drug is dispersed homogeneously in the matrix. The characteristics of 
matrix devices are: 
1. Zero order release will not be obtained 
2. Formulation is easy than reservoir devices 
3. For higher molecular weight compounds, this system is used. 
 
 
Fig.2 Schematic Representation of Diffusion Type Matrix System       
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RESERVOIR DEVICES OR SYSTEMS  
In this, the drug core or reservoir is surrounded by a polymeric membrane 
which acts as the rate limiting barrier for the release of drug. The characteristics of the 
reservoir devices are: 
1. Zero order release is obtained 
2. The rate of release of the drug depends on the polymer used 
3. Delivery of higher molecular weight compounds is difficult. 
 
 
Fig.3: Schematic Representation of Diffusion Type Reservoir System 
 
DISSOLUTION CONTROLLED RELEASE SYSTEMS 
These are comparatively easy to formulate. The drugs used in this system will 
have slow dissolution rate (Griseofulvin and Digoxin). Drugs with high aqueous 
solubility and dissolution rate cannot be used for this type of drug delivery. 
Dissolution controlled release systems can be formulated by incorporating the drug in 
an insoluble polymer and coating the drug particle with polymeric material of varying 
thickness. This is done in order to control the release of the drug in the gastro-
intestinal medium. The diffusion across the aqueous boundary layer acts as the rate 
limiting step. 
The rate of dissolution (dm/dt) can be found out by: 
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dm/dt = ADS/h 
 
S = Aqueous solubility of drug 
A = Surface area of tablet  
D = Diffusivity of drug 
H = Thickness of boundary layer. 
 
MATRIX DISSOLUTION CONTROLLED SYSTEMS 
In this, bees wax, carnauba wax are used which determines the drug release 
rate by controlling the rate of penetration of fluid into the matrix. The drug release 
from these systems is based on first order kinetics. 
 
                              
  Fig.4: Schematic Representation of Dissolution type Matrix System 
                                 
RESERVOIR DISSOLUTION CONTROLLED SYSTEMS 
In this, the drug particles are encapsulated by different micro encapsulation 
techniques with poly ethylene glycol and cellulose. The dissolution rate depends on 
solubility of coat and thickness of coating. 
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Fig 5: Schematic Representation of Dissolution type Reservoir System 
                                              
OSMOTIC CONTROLLED SYSTEMS 
 The osmotic drug delivery is useful for poorly soluble drug, pulsative drug 
release and zero order release. The different techniques used for the formulation of 
osmotic drug delivery system include push-pull osmotic pump, osmotic bursting 
osmotic pump, liquid oral osmotic system, sandwiched osmotic tablets etc. In these 
systems, the controlled delivery of drug is due to the change in osmotic pressure. The 
delivery of drug in the system is independent of the physiological factors in the 
gastrointestinal tract. Factors that affect the release of the drug are solubility and 
osmotic pressure of the core, size of the delivery orifice and nature of the rate 
controlling membrane. 
 
 Fig. 6: Type-A osmotic system            Fig.7: Type-B osmotic system 
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BIODEGRADABLE POLYMERIC DRUG DELIVERY SYSTEM 
Nanoparticles made from solid lipids are attracting increasing attention as 
colloidal drug carriers for iv application. The nanoparticles range as 50-1000nm and 
they are composed of physiological lipids. These particles are in solid state at room 
temperature, so the mobility of incorporated drugs is reduced. They are stabilized with 
non-toxic surfactants like polaxamer and lecithin. Due to the production by high 
pressure homogenization they can be produced on large industrial scale. In addition, 
this production method avoids the use of organic solvents. Compared to traditional 
carriers the SLN have compared advantages of polymeric nanoparticles and o/w fat 
emulsions for parenteral administration.  There are several studies are conducted for 
the optimization of production parameters, long term stability, recrystallisation 
behaviour, morphological characterization and in -vivo toxicity have been undertaken. 
A basic problem in early work with lipid particles in the nanometre range was the 
generally observed burst release of drugs; a prolonged release could not be achieved. 
The aim of the investigation was therefore, to assess if a prolonged release is basically 
possible.   
POLYMERS USED IN SUSTAINED RELEASE TABLETS8,9  
Sustained release drug delivery means not only prolonged duration of drug 
delivery but also implies predictability and reproducibility of drug release kinetics. 
The polymers used for the sustained release drug delivery should retard the release of 
drug. Usually natural acrylic and cellulose polymers have been used for formulating 
sustained release formulations. Now a day, microencapsulation is selected for 
designing sustained release formulations where thin coatings are applied to small 
particles of solids or liquids. Microencapsulation by natural products such as starch, 
proteins, waxes are also done.  
HPMC, chitosan and sodium alginate are the most preferable polymers as they 
are non-toxic, biocompatible, and biodegradable and can be easily modified by 
physical and chemical means. Methyl cellulose has long chain substituted polymers 
which is used as binding, disintegrating and suspending agent where as sodium 
carboxy methyl cellulose is a salt of poly carboxy methyl ether of cellulose which is 
used as coating, binding, stabilising and suspending agent. Poly vinyl pyrrolidone 
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(PVP) is 1-ethenyl-2-pyrrolidonone homo polymer which is used as disintegrant, 
dissolution aid, suspending agent and tablet binder. 
Now a days, natural binders are also used widely for formulating sustained 
release tablets as they are less toxic, biodegradable, easily available and low cost. 
Different natural agents like starches, gums, mucilage have binding, disintegrating, 
and filler activities. Different starches like rice, potato, tapioca and seeds of Cassia 
roxburghii and tamarind seed powder and gums like okra gum, neem gum, olibanum 
gum etc are used for formulating sustained release formulations. 
The Cassia roxburghii seeds are collected and its size is get reduced by 
hammer milling and is powdered. This is soaked in water for one day and is extracted 
by filtration. The gum is get separated by centrifugation and it is dried. The gum at 
different concentration is used for formulating the sustained release tablets. 
The tamarind seeds are collected from the tamarind tree and are heated with 
sand for some time. This is done to remove the outer coating of the seed and it is 
hammer milled for size reduction of the seed. Then it is grinded and is passed through 
sieve number 100.  
The tapioca tubers are collected and are peeled, washed and cut into small 
pieces. Then it is soaked in water for one hour. The whole mass is milled in to fine 
powder and is dried and is sieved using sieve number 100. 
The neem exudate is collected from the bark, it is hydrated in distilled water. 
Extraneous material was removed, dried and powdered. It is passed through sieve 
number 100. 
MECHANISM OF DRUG RELEASE FROM THE TABLET10,11,12  
Drug in the outside layer exposed to the bathing solution is dissolved first and 
then diffuses out of the matrix. This process continues with the interface between the 
bathing solution and the solid drug moving towards the interior. It follows that for this 
system to be diffusion controlled, the rate of dissolution of drug particles within the 
matrix must be much faster than the diffusion rate of dissolved drug leaving the 
matrix.  
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Derivation of the mathematical model to describe this system involves the 
following assumptions: 
A pseudo-steady state is maintained during drug release, 
The diameter of the drug particles is less than the average distance of drug 
diffusion through the matrix,  
The bathing solution provides sink conditions at all times.  
The release behaviour for the system can be mathematically described by the 
following equation: 
 
dM/dh = Co. dh - Cs/2 
Where,  
dM  = Change in the amount of drug released per unit area.  
dh  = Change in the thickness of the zone of matrix that has  
been depleted of drug.  
Co  =  Total amount of drug in a unit volume of matrix. 
Cs  =  Saturated concentration of the drug within the matrix. 
 
Additionally, according to diffusion theory: 
dM = ( Dm. Cs / h) dt 
 
Where, 
Dm = Diffusion coefficient in the matrix. 
h  = Thickness of the drug-depleted matrix.  
dt  =  Change in time.  
 
By combining equation 1 and equation 2 and integrating:  
 
M = [Cs. Dm (2Co −Cs) t] ½ 
 
When the amount of drug is in excess of the saturation concentration then:  
M = [2Cs.Dm.Co.t] 1/2 
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Equation 3 and equation 4 relate the amount of drug release to the square-root 
of time. Therefore, if a system is predominantly diffusion controlled, then it is 
expected that a plot of the drug release vs. square root of time will result in a straight 
line. Drug release from a porous monolithic matrix involves the simultaneous 
penetration of surrounding liquid, dissolution of drug and leaching out of the drug 
through tortuous interstitial channels and pores. 
The volume and length of the openings must be accounted for in the drug 
release from a porous or granular matrix: 
 
M = [Ds. Ca. p/T. (2Co – p.Ca) t] 1/2 
 
Where,  
p = Porosity of the matrix.  
t = Tortuosity. 
Ca  = solubility of the drug in the release medium. 
Ds  =  Diffusion coefficient in the release medium.  
T =  Diffusional path length.  
 
For pseudo steady state, the equation can be written as: 
M = [2D.Ca .Co (p/T) t] ½  
  
The total porosity of the matrix can be calculated with the following equation: 
p = pa + Ca/ ρ + Cex / ρex 
 
Where, 
p  = Porosity.  
ρ  = Drug density.  
pa  = Porosity due to air pockets in the matrix.  
ρex  = Density of the water soluble excipients.  
Cex  = Concentration of water soluble excipients.  
 
For the purpose of data treatment, equation 7 can be reduced to: 
M = k. t 1/2 
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Where, k is a constant, so that the amount of drug released versus the square 
root of time will be linear, if the release of drug from matrix is diffusion-controlled. If 
this is the case, the release of drug from a homogeneous matrix system can be 
controlled by varying the following parameters: 
 Initial concentration of drug in the matrix.  
 Porosity.  
 Tortuosity. 
 Polymer system forming the matrix.  
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2. REVIEW OF LITERATURE  
 
Singh AK et al13, prepared matrix tablets of aceclofenac by direct compression 
process using natural gums (xantham gum and karaya gum) in different ratios. The 
effect of natural gums on the release profile of drug from matrix system for once daily 
sustained release tablets formulations were evaluated. The in-vitro release of drug was 
performed in phosphate buffer of pH 7.4 for 24 hours. . The tablets with FXK resulted 
in more uniform controlled drug release matrices than FX and FK formulations. . 
Xantham gum matrices showed good sustained effect on the release of aceclofenac 
than FK alone matrices. The FXK formulation was found to provide the required 
release rate, with zero-order release kinetics. It is cost effective and more similar to 
reference standard. 
 
S.Jaganath et al14, prepared and evaluated silymarin controlled release tablets 
using natural gum polymers like xantham gum and guar gum in the drug polymer 
ratio of 1:0.25, 1:0.5 and 1:0.75. The in vitro release study was performed using 
900ml of phosphate buffer of pH7.4 for 10 hours using USP type II dissolution 
apparatus. The in vitro drug release of silymarin from the formulation without 
polymer was found to be 99% in 3.5 hours. When the polymer ratio was increased, the 
percentage drug release of silymarin was decreased. The silymarin, xantham gum 
combination in the ratio of 1:0.75 showed the in vitro drug release of 73.92%, thus 
sufficiently sustaining the release of drug. 
 
Azharuddin et al15, prepared and evaluated controlled release matrix tablets of 
losartan potassium by direct compression using natural polymer like xantham gum 
and synthetic hydrophilic polymer like HPMC. Results of this study confirmed that 
the polymer concentration plays a major role in drug release. It was observed that 
with increasing concentration of the polymer, the percentage of drug release was 
decreased.  
 
Roohullah et al16, prepared and evaluated various formulations of sustained-
release matrix tablets of carbamazepine. The matrix tablets were prepared by solvent 
evaporation method using hydroxypropyl methyl cellulose (HPMC), carboxy methyl 
cellulose (CMC) and polyvinylpyrrolidon-K90 (PVP-K90) as release sustaining 
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materials. Formulations were designed to develop twice daily sustained release 
dosage form. . HPMC based matrix tablets with the drug to polymer ratio of 1:2 was 
found to sustain the release of the carbamazepine up to 12 hours, while CMC and 
PVP-K90 with drug to polymer 1:2 ratio was able to control the drug release up to 8 
and 6 hours respectively. The stability study also confirmed that the drug is stable in 
HPMC based matrix tablets. So HPMC was selected as the best polymer to formulate 
the sustained release formulation of carbamazepine for 12 hours. 
 
Asaduzzaman et al17, designed and evaluated oral sustained release matrix 
tablets of ranolazine by wet granulation using Methocel K4M CR as the retardant 
polymer. In vitro release studies were performed using USP type II apparatus (paddle 
method) in 900 ml of 0.1N hydrochloric acid at 50 rpm for 8 hours. Based on the 
dissolution data comparison with the standard, F-5 formulation (16% Methocel K4M 
CR w/w of drug) was elected as the best formulation. They concluded that the oral 
sustained release tablets of ranolazine provided a better option for development of a 
twice daily formulation of the drug. 
 
Emeje et al18, prepared oral sustained release matrix tablets of zidovudine 
(ZDV) using different types, proportions and blends of carbopol 71G (C71) and a 
plant gum obtained from Abelmoschus esculentus (AEG). The effect of various 
formulation factors like polymer proportion, polymer type and pH of the dissolution 
medium on the in vitro release of the drug was studied, using the half change 
technique, in 900 ml of dissolution medium, at 100 rpm. The results of drug 
dissolution studies showed improved drug release retardation effects of the polymer 
blends. Blending a natural gum with a synthetic polymer could achieve equivalent or 
better performance while being more economical. 
 
Raghavendra Rao et al19, formulated and evaluated sustained release matrix 
tablets of water soluble tramadol hydrochloride using different polymers like hydroxy 
propyl methyl cellulose (HPMC) and natural gums like karaya gum (KG) and 
carrageenan (CG). The in vitro release study was performed in 0.1 N hydrochloric 
acid of pH 1.2 for 2 hours and in phosphate buffer of pH 6.8 up to 12 hours. The 
effect of polymer concentration and polymer blend concentration were studied. It was 
observed that matrix tablets that contained polymer blend of HPMC/CG successfully 
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sustained the release of drug upto 12 hours. Among all the formulations, formulation 
F16 which contained 20% HPMC K15M and 80% of CG released the drug which 
followed zero order kinetics by swelling, diffusion and erosion and the release profile 
of formulation F16 was comparable with the marketed product. Stability studies 
(40±2ºC/75±5%RH) for 3 months indicated that tramadol hydrochloride was stable in 
the matrix tablets. 
 
Mughal et al20, developed propranolol hydrochloride-loaded matrix tablets 
using guar gum, xantham gum, and hydroxypropyl methylcellulose (HPMC). Tablets 
were prepared by wet granulation using these polymers alone and in combination, and 
physical properties of the granules and tablets were studied. Drug release was 
evaluated in simulated gastric and intestinal media. It was concluded that these 
polymers can be used to formulate successful sustained release propranolol 
hydrochloride matrix tablets that have desirable characteristics. 
 
Basavaraj et al21, developed and evaluated sustained release formulation of 
aceclofenac based on monolithic matrix technology. The tamarind seed 
polysaccharide (TSP) was extracted from tamarind kernel powder and this 
polysaccharide was utilized in the formulation of matrix tablets containing 
aceclofenac by wet granulation technique and evaluated for its drug release 
characteristics. Formulation was optimized on the basis of acceptable tablet properties 
like hardness, friability, drug content and weight variations. The in vitro drug release 
and stability studies were also conducted. The results indicated that a decrease in 
release kinetics of the drug was observed by increasing the polymer concentration. 
They concluded that the matrix tablets were found to be effective in sustaining the 
drug release up to 12 hours. 
 
Afrasim et al22, formulated of sustained release matrix tablets of diltiazem 
hydrochloride (DTZ) using cross-linked karaya gum [modified karaya gum (MK)]. 
Modified karaya gum (MK) was prepared by cross-linking karaya gum with tri-
sodium tri-metaphosphate (STMP) which was used as a cross linker. Matrix tablets of 
DTZ were prepared using varying ratios of unmodified karaya gum (K) and MK by 
direct compression.  Drug release was by water uptake, diffusion and erosion 
mechanisms. Tablets formulated with MK showed higher mean dissolution time 
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(MDT) and lower dissolution efficiency than those prepared with karaya gum. Drug 
release for tablets prepared with pure K was 99.9 % at the end of 10 hours while the 
tablet made with MK was 68.2 % at the end of 12 hours. MK sufficiently controlled 
the drug release unlike K which exhibited rapid drug release efficiency. The results of 
the study showed that modified karaya gum is a potential matrix material for 
formulating suitable sustained-release matrix tablets of diltiazem. 
 
Saha et al23, developed  oral controlled release matrix tablet formulations of 
isoniazid using hydroxypropyl methylcellulose (HPMC) as a hydrophilic release 
retardant polymer and  studied the influence of various formulation factors like 
proportion of the polymer, polymer viscosity grade, compression force, and release 
media on the in vitro release characteristics of the drug. The formulations were 
developed using wet granulation technology. They concluded that the hydrophilic 
polymer like HPMC could be used as a matrix material to design controlled release 
formulations of a water-soluble drug isoniazid with desired quality and release 
characteristics. 
 
S. Brito Raj et al24, prepared bilayer tablet of metformin hydrochloride (SR) 
with metoprolol tartarate (IR) as a once daily formulation. The formulations of tablets  
were prepared by using release retarding agents like HPMC K100, Eudragit S 100 for 
sustained release (SR) layer and super disintegrants like crosspovidone, sodium starch 
glycolate (SSG) for immediate release (IR) layer. Both sustained and immediate 
release granules were evaluated for flow property. Bilayer tablets were evaluated for 
weight variation, hardness, thickness, swelling index and in-vitro drug release for 12 
hours. All the formulations obey zero order release kinetics and the mechanism of 
drug release was found to be non fickian diffusion by fitting the data to peppas 
equation. The results suggested that the developed bilayer tablet of metformin 
hydrochloride (SR) with metoprolol tartarate (IR) could perform therapeutically better 
and improved efficacy than conventional dosage forms. 
 
Jekku et al25, designed and characterized sustained release matrix tablets of 
glimepiride by using synthetic and natural polymers. Sustained release tablets of 
glimepiride was prepared by wet granulation method using various concentrations of 
synthetic polymers (HPMC K 15M & HPMC K 4M) and natural polymers (starch 
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acetate & starch urea). The study revealed that the various concentrations of natural 
polymers (starch acetate & starch urea) sustained the drug release when compared to 
synthetic polymers (HPMC K 15M & HPMC K 4M). Among all the formulations F-
12 formulation with starch urea at the concentration of 30% was found to have more 
sustained action when compared to other formulations with the same concentration of 
other polymers and it showed drug release of 49.70 % at the end of 7hours. 
 
Deepthi Kodam et al26, formulated and evaluated sustained release matrix 
tablets of tramadol hydrochloride using different hydrophilic and hydrophobic 
polymers like hydroxyl propyl methylcellulose, polyethylene oxide, ethyl cellulose 
and eudragit. All the batches were evaluated for angle of repose, Carr’s index, 
Hausner ratio, hardness, thickness, weight variation, drug content and in-vitro release 
characteristics. The optimized tablets having HPMC provided more sustained drug 
release than other polymers. FTIR studies indicated that there was no interaction 
between the drug and excipients and stability studies had proved the integrity of the 
developed matrix tablets. 
 
Arul Kumaran KSG et al9, formulated and evaluated tablets of paracetamol 
and diclofenac sodium using Cassia roxburghii seed gum powder as binder. The 
study revealed that Cassia roxburghii seed gum powder is a better binder for 
preparing tablet since it minimized the capping tendency without adversely affecting 
other crucial properties of the tablet. Cassia roxburghii gum produced tablets with 
longer disintegration time and longer dissolution time than tablets with standard 
starch binder.  
 
Habeeb MD et al27, developed sustained release bilayer tablets of water soluble 
drug tramadol hydrochloride using guar gum, HPMC, NaCMC and xantham gum, 
either alone or in combinations. Tablets were prepared by direct compression for 
immediate release and wet granulation method for sustained release and evaluated for 
various physical parameters. The drug release studies were performed using USP 
apparatus type І using 0.1N hydrochloric acid and phosphate buffer of pH 6.8 as 
dissolution medium. The drug release was dependent on the type and concentration of 
the polymer. Drug release was faster from tablets prepared with guar gum, NaCMC 
and HPMC alone. However, in combination with HPMC, NaCMC, guar gum with 
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xantham gum it sustained drug release effectively. All the formulations followed zero 
order release mechanism. Higuchi plots for all the formulations were linear indicating 
the drug release by diffusion controlled. Hixon-Crowell cube root model showed high 
r2 value proportionality due to erosion of hydrophilic gel layer. To explore the release 
pattern, results of the in-vitro dissolution data were fitted to the Korsmeyer-Peppas 
equation, which characterizes the transport mechanism indicates the non fickian 
transport it refer to combination of both diffusion and erosion rate release. 
 
T. Sivakumar et al28, formulated and characterised controlled release tablets 
containing the natural gum obtained from Mangifera indica. The dissolution study of 
the tablet revealed that the formulation containing 5%w/w of the gum performed as a 
better binding agent than the standard binder gum acacia at the same concentration. 
The study also revealed that Mangifera indica gum is pH sensitive and therefore it can 
be used in the formulation of intestinal drug delivery systems. 
 
Jaleh Varshosaz et al29, developed matrix sustained release tablets of highly 
water-soluble tramadol hydrochloride using natural gums like xantham gum (X gum) 
and guar gum (G gum) and hydrophilic matrices like hydroxypropyl methylcellulose 
[HPMC] or carboxymethyl cellulose [CMC]. Matrix tablets were prepared by direct 
compression method. Different ratios of 100:0, 80:20, 60:40, 20:80, 0:100 of G gum 
(or X): HPMC, X gum:G gum, and triple mixture of these polymers (G gum, X gum, 
HPMC) were applied. After evaluation of physical characteristics of tablets, the 
dissolution test was performed in the phosphate buffer media of pH 7.4 for 8 hours. 
Guar gum alone cannot efficiently control drug release, and X gum has higher drug 
retarding ability than G gum. The combination of each natural gum with HPMC leads 
to a greater retarding effect compared with a mixture of two natural gums. 
 
Amit S Yadav et al30, prepared oral controlled release zidovudine matrix tablets 
by using guar gum as rate controlling polymer and to evaluate drug release parameters 
as per various release kinetic models. The tablets were prepared by wet granulation 
method. Granules were prepared and evaluated for loose bulk density, tapped density, 
compressibility index and angle of repose and the tablets exhibited satisfactory 
results. The in-vitro dissolution study was carried out for 12 hours using paddle (USP 
type II) method in phosphate buffer of pH 6.8 as the dissolution medium. Among all 
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the formulations, the formulation with 15% of guar gum shows 95.97% of drug 
release at the end of 12 hours. Selected formulation was subjected to stability studies 
for 3 months, which showed stability with respect to release pattern. Fitting the in-
vitro drug release data to Korsmeyer equation indicated that diffusion along with 
erosion could be the mechanism of drug release. 
 
Sajid Ali et al31, prepared and evaluated sustained release matrix tablets of 
phenytoin sodium using natural polymers. The tablets were prepared by the wet 
granulation method using water as granulating agent along with matrix materials like 
guar gum, sodium alginate, tragacanth and xantham gum with varying percentage. 
The mechanism of drug release was diffusion coupled with erosion. Guar gum alone 
could not control the phenytoin release effectively for 12 hours. It was evident from 
the results that matrix tablet formulated using 55%  guar gum with 10%  gum acacia 
with water as granulating agent was the best formulation for the sustained release 
matrix tablets of phenytoin. 
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3. AIM AND OBJECTIVE 
AIM 
The aim of this investigation is to formulate and evaluate paliperidone 
sustained release tablets using natural polymers and to compare with standard rate 
retardant polymer HPMC. 
GENERAL OBJECTIVE 
To estimate the binding capacity of various natural gums in granules and tablet 
formulations as a release retardant. 
 
SPECIFIC OBJECTIVES 
 To collect and isolate gums from different natural sources. 
 To prepare granules by direct compression method and determine their 
physical properties. 
 To optimise the binder concentration using appropriate experimental design. 
 To prepare and compress tablets of the optimum formulation and compare 
with standard rate retardant polymer, HPMC. 
 To evaluate the in vitro release principle of sustained release paliperidone 
tablets and evaluate the release mechanism on the behalf of various kinetic 
modules. 
 To perform the stability study on optimised paliperidone formulation. 
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4. PLAN OF WORK 
 
1. Review of literature 
2. Collection and isolation of the gums from different natural sources 
3. Preformulation studies 
  Bulk density 
 Tapped density 
 Carr’s index 
 Hausner’s ratio 
 Angle of repose 
4. Preparation of tablet by direct compression method 
5. Post formulation studies 
 Hardness 
 Friability 
 Weight variation 
 Content uniformity  
 Assay     
 Dissolution studies 
6. Kinetic analysis 
 First order 
 Zero order 
 Higuchi order 
7. Stability studies 
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5. DRUG PROFILE32,33,34,35 
Paliperidone also known as 9-hydroxyrisperidone, is an atypical 
antipsychotic developed by Janssen Pharmaceutica. Chemically, paliperidone is the 
primary active metabolite of the older atypical antipsychotic risperidone. Paliperidone 
is 9-hydroxyrisperidone, i.e. risperidone with an extra hydroxyl group). It is indicated 
for the acute and maintenance treatment of schizophrenia 
 
 IUPAC:  
   (RS)-3-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl] ethyl] 7-
hydroxy -4 -methyl-1, 5-diazabicyclo[4.4.0]deca-3,5-dien-2-one. 
 
 Molecular formula:  
   C23H27FN4O3 
 
 Molecular Structure: 
                          Chemical structure of paliperidone.  
          
* indicates position of chiral carbon atom. 
 
 Mol. mass:  
   426.484 g/mol 
 Bioavailability: 
   28% (oral) 
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 Half-life:  
   23 hours (oral) 
 
 Solubility:  
          Paliperidone is sparingly soluble in 0.1N HCl and methylene chloride; 
practically insoluble in water, 0.1N NaOH, hexane; and slightly soluble in N, N-
dimethylformamide. 
 
 Pharmacology: 
    The exact mechanism of action of paliperidone is unknown; it is 
believed that the action of paliperidone and respiridone are similar, if not in 
identical pathways. Therapeutic effect may be due to a combination of D2 and 
5-HT2A receptor antagonism. Paliperidone also has antagonist effect at α1 and 
α2 adrenergic receptors and at H1 histamine receptors. It does not bind to 
muscarinic acetylcholine receptors. 
 
 Dose: 
   Extended-release tablets 3 mg, 6 mg , 9 mg and 12 mg. 
 
 Side Effects and Adverse Reactions 
 The common side effects of paliperidone are restlessness and 
extrapyramidal disorder, including involuntary movements, tremors and 
muscle stiffness. There may be chances for sexual dysfunction while 
administering this drug in combination with SSRIs. 
 Neuroleptic malignant syndrome is a rare, but potentially lethal reaction 
to the medication. Heart rhythm changes potentially serious may make 
paliperidone risky for people with some heart conditions. 
 Tardive dyskinesia, is permanent side effect reported with paliperidone 
and other neuroleptics. The risk of tardive dyskinesia increases with total 
dose and thus becomes more likely the longer a person takes 
paliperidone. 
 High blood sugar, hyperprolactinemia or elevated levels of the hormone 
prolactin, potentially leading to the absence of a menstrual period, 
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breasts producing milk, the development of breasts by males and erectile 
dysfunction are also seen. 
 Complications associated with pre-existing narrowing or blockage of the 
gastrointestinal tract (esophagus, stomach or small or large intestine). 
 Fainting or light-headedness when standing up or sitting up too quickly. 
 Risk in people with a seizure disorder or a history or health conditions 
that make seizures. 
 Caution should be exercised before prescribing paliperidone to pregnant 
or nursing women.   
 Associated with decreases in the counts of white cells in circulating 
blood. 
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6. DISEASE PROFILE36 
 
Schizophrenia is a brain disorder that distorts the way a person thinks, acts, 
expresses emotions, perceives reality and relates to others. Depression is an illness 
that is marked by feelings of sadness, worthlessness or hopelessness, as well as 
problems concentrating and remembering details. Bipolar disorder is characterized by 
cycling mood changes, including severe highs (mania) and lows (depression). 
Schizoaffective disorder is a life-long illness that can impact all areas of daily 
living, including work or school, social contacts and relationships. Most people with 
this illness have periodic episodes, called relapses, when their symptoms surface. 
While there is no cure for schizoaffective disorder, symptoms often can be controlled 
with proper treatment. 
 
 Symptoms of Schizoaffective Disorder 
A person with schizoaffective disorder has severe changes in mood and some 
of the psychotic symptoms of schizophrenia, such as hallucinations, delusions and 
disorganized thinking. Psychotic symptoms reflect the person's inability to tell what is 
real from what is imagined. Symptoms of schizoaffective disorder may vary greatly 
from one person to the next and may be mild or severe. Symptoms of schizoaffective 
disorder may include: 
 
 Depression  
 Poor appetite  
 Weight loss or gain  
 Changes in sleeping patterns (sleeping very little or a lot)  
 Agitation (excessive restlessness)  
 Lack of energy 
 Loss of interest in usual activities  
 Feelings of worthlessness or hopelessness  
 Guilt or self-blame  
 Inability to think or concentrate  
 Thoughts of death or suicide 
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 Mania 
 Increased activity, including work, social and sexual activity  
 Increased and/or rapid talking  
 Rapid or racing thoughts  
 Little need for sleep  
 Agitation  
 Inflated self-esteem  
 Distractibility  
 Self-destructive or dangerous behavior (such as going on spending 
sprees, driving recklessly or having unsafe sex) 
 
 Schizophrenia  
 Delusions (strange beliefs that are not based in reality and that the 
person refuses to give up, even when presented with factual 
information)  
 Hallucinations (the perception of sensations that aren't real, such as 
hearing voices)  
 Disorganized thinking  
 Odd or unusual behaviour  
 Slow movements or total immobility  
 Lack of emotion in facial expression and speech  
 
 Causes of Schizoaffective Disorder 
While the exact cause of schizoaffective disorder is not known, researchers 
believe that genetic, biochemical and environmental factors are involved.  
 Genetics (heredity): A tendency to develop schizoaffective disorder 
may be passed on from parents to their children.  
 Brain chemistry: People with schizophrenia and mood disorders 
may have an imbalance of certain chemicals in the brain. These 
chemicals, called neurotransmitters, are substances that help nerve 
cells in the brain send messages to each other. An imbalance in these 
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chemicals can interfere with the transmission of messages, leading to 
symptoms.  
 Environmental factors: such as a viral infection, poor social 
interactions or highly stressful situations -- may trigger 
schizoaffective disorder in people who have inherited a tendency to 
develop the disorder. 
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7. POLYMER PROFILE37 
HYDROXY PROPYL METHYL CELLULOSE 
 
Non-proprietary Names : 
BP    :  Hypromellose 
JP    :  Hypromellose 
PhEur    :  Hypromellose 
USP    :  Hypromellose 
Synonyms:  
Benecel MHPC, E464, hypromellosum; Methocel; methylcellulose propylene 
glycol ether; methyl hydroxylpropyl cellulose; Metolose; MHPC; Pharmacoat; 
Tylopur; Tylose MO. 
 
Chemical Name  : Cellulose hydroxypropyl methyl ether  
 
Structural Formula: 
 
 
Where R is H, CH3, or CH3CH (OH) CH2 
 
Descriptions:  
Hypromellose is an odorless and tasteless, white or creamy white fibrous or 
granular powder.  
Typical Properties: 
Acidity/alkalinity   :  pH = 5.5–8.0 for a 1% w/w   
   aqueous  solution. 
Ash     : 1.5–3.0% 
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Autoignition temperature  : 360ºC 
Density (bulk)   : 0.341 g/cm3 
Density (tapped)   : 0.557 g/cm3 
Density (true)   : 1.326 g/cm3 
Melting point    : browns at 190–208ºC; chars at  
225–238ºC. 
Glass transition temperature : 170–180ºC. 
Loss on drying    :  < 10.0% 
Residue on ignition   : 1.0% 
Maximum Limits of Impurities: 
Arsenic                <3PPM 
Heavy metals       <0.001% 
Methoxy (Percent) 23.2 
Hydroxy propoxy (Percent) 8.5 
 
Moisture content    
Hypromellose absorbs moisture from the atmosphere; the amount of water 
absorbed depends upon the initial moisture content and the temperature and relative 
humidity of the surrounding air.  
 
Solubility      
Soluble in cold water, forming a viscous colloidal solution; practically 
insoluble in chloroform, ethanol (95%), and ether, but soluble in mixtures of ethanol 
and dichloromethane, mixtures of methanol and dichloromethane, and mixtures of 
water and alcohol.  
 
Specific gravity  :  1.26 
 
Functional Category  
Coating agent; film-former; rate-controlling polymer for sustained release; 
stabilizing agent; suspending agent; tablet binder; viscosity-increasing agent. 
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Pharmaceutical Applications 
Hypromellose is widely used in oral, ophthalmic and topical pharmaceutical 
formulations. In oral products, hypromellose is primarily used as a tablet binder, in 
film-coating, and as a matrix for use in extended-release tablet formulations. 
Concentrations between 2% and 5% w/w may be used as a binder in either wet- or 
dry-granulation processes. High-viscosity grades may be used to retard the release of 
drugs from a matrix at levels of 10–80% w/w in tablets and capsules. Depending upon 
the viscosity grade, concentrations of 2–20% w/w are used for film-forming solutions 
to film-coat tablets. 
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CASSIA ROXBURGHII GUM 
Synonym   : Ceylon Senna, Red Cassia, Horse Cassia 
Source   : It is the gum obtained from the seeds of  
     Cassia roxburghii 
Family   : Fabaceae/Leguminosae 
Physicochemical Properties: 
pH    : 6.5 
Viscosity   : .876 poise  
 Bulk Density   :  0.69g/ml 
 Tappped Density  :  0.81g/ml 
 Angle of Repose  :  37.56º 
 Carr's Index   :  14.81% 
          Swelling Ratio  :  6.2 
Hausner's Ratio  :  1.17 
Solubility   : Dissolves in warm water forming a  
colloidal solution swells in cold water 
insoluble in organic solvents 
Stability   :  The gum is normally stable at  
moderate temperature and pressure. 
Storage   :   Stored in a cool, dry place 
Pharmaceutical  
Applications   :  The gum is used in slow release  
formulations. It is used especially when 
high mechanical strength is needed. 
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NEEM GUM 
Synonym   :  Indian lilac, Margosa 
Source   :  It is a typical plant gum exudated from  
      the tree Azadirachta indica. 
Family   :  Meliaceae 
Chemical Constituents : Nimbin, Nimbinin, Nimbosterol,  
      Mannose, Glucosamine, Arabinose,  
      Galactose, Fructose, Xylose and Glucose 
                      
Structure of Nimbin 
Physicochemical Properties: 
pH   :  6.7±0.5 
Viscosity  :  1.1032 poise  
Bulk Density  :  0.611g/ml 
Tappped Density :  0.710g/ml 
Angle of Repose :  28.711º 
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Carr's Index  :  12.983% 
Solubility  :  Very soluble in warm water  
                      Partially soluble in cool water. 
Stability  :  The gum is normally stable at moderate  
temperature and pressure. 
Storage  :   Stored in a tightly closed container. 
Pharmaceutical  
Applications  : The neem gum is used as binding agent,  
suspending agent and transdermal film forming 
agent. 
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TAMARIND GUM 
Source   : Tamarind gum is obtained from the  
     endosperm of seeds of the tamarind tree,  
     Tamarindus indica.  
Family   : Leguminoseae 
Chemical Constituents : Tamarind seed gum, a crude extract of  
tamarind seeds, is rich in polysaccharide, which 
contains glucose, xylose and galactose units, in a 
molecular ratio of 3:2:1 
Physicochemical Properties: 
pH   : 6.81±0.21 
Viscosity  : 0.8928 poise  
Moisture Content :  10.78% 
Ash Content  :  0.39% 
Swelling Index  :  1700.56% 
Water Retention :  20.34% 
True Density  : 1.015g/ml 
Bulk Density  :  0.651g/ml 
Tappped Density : 0.781g/ml 
Angle of Repose : 29.51º 
Carr's Index  :  16.64% 
Solubility  :  Quickly soluble in warm water forming a  
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viscous colloidal solution sparingly soluble in 
cold water insoluble in ethanol, methanol, 
acetone and ether   
Stability  :  The gum is stable at temperature less than  
30ºC 
Storage   :   Stored in a well closed container. 
Pharmaceutical  
Applications  :  The tamarind gum is used as binding  
agent, emulsifier, suspending agent, sustaining 
agent. It is also used to improve dissolution, to 
prolong nasal mucoadhesion. 
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TAPIOCA STARCH 
Synonym  :  Manioc, Yuca, Mogo, Mandioca 
Source  :  Tapioca starch is obtained from the tuberous  
    root of  the tapioca plant, Manihot esculenta  
Family  :  Euphorbiaceae 
Chemical  
Constituents  :  Reducing sugar, Non-reducing sugar, Protein  
    and Fibre 
Physicochemical Properties: 
pH    : 6.56 
Viscosity   : .987 poise  
Moisture Content  :  10-13% 
Ash Content   :  0.4% 
Bulk Density   :  0.714g/ml 
Tappped Density  :  0.892g/ml 
Angle of Repose  :  31.28º 
Carr's Index   :  14.49% 
Solubility   :  Quickly soluble in warm water. 
Stability   : The gum is normally stable at  
moderate temperature and pressure.  
Storage    :  Stored in a tightly closed container 
Pharmaceutical  
Applications   :  It is widely used in pharmaceuticals,  
primarily as a binder/ diluents.  
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MICROCRYSTALLINE CELLULOSE 
 
Structural formula: 
 
Non-proprietary name:            
 BP    : Microcrystalline cellulose 
 JP    : Microcrystalline cellulose 
 PhEur   : Cellulosum microcrystallinum 
 USPNF  : Microcrystalline cellulose 
 
Synonym   : Avicel; Cellulose gel; tabulose                                                
Crystalline cellulose; E460; Emcocel                                              
Fibrocel; vivacel                                                            
Chemical name  :  Cellulose 
Empirical formula  : (c6H10O5)n  
Molecular weight  :  ≈36000 where n≈220. 
Functional category  :  Adsorbent; suspending agent; capsule  
and tablet diluents; tablet disintegrant.  
Physical state   : It is a purified, partially depolymerised.  
Cellulose that occurs white odourless, Tasteless, 
crystalline powder composed of porous 
particles. It is commercially available in 
different particle size and moisture grades which 
have different properties and applications. 
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Typical properties:           
Density (bulk)  :  0.337 g/cm3 
Density (tapped)    : 0.478 g/cm3 
Density (true)  : 1.512-1.668 g/cm3 
Melting point   : Chars at 260-270oC 
Moisture content  : Less than 5% w/w 
Solubility   : Slightly soluble in 5%w/sodium  
Hydroxide solution, practically insoluble in 
water, dilute acids, and most Organic solvents. 
Stability and storage  
Condition   : Microcrystalline cellulose is a stable,  
though hygroscopic material. The bulk material 
should be stored in a well closed container in a 
cool,dry,place.  
Incompatibility  :  Incompatible with strong Oxidizing  
agents. 
Pharmaceutical  
Applications   : It is widely used in pharmaceuticals,  
primarily as a binder/ diluents in oral tablet and 
capsule formulations where it is used in both wet 
granulation and direct compression processes. 
Microcrystalline cellulose also has some 
lubricant and disintegrant properties that make it 
useful in tableting. It is also used in cosmetics 
and food products. 
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TALC 
 
Non-proprietary Names 
BP    : Purified Talc 
JP    :  Talc 
PhEur    :  Talc 
USP    :  Talc 
Synonyms: 
  Altalc; E553b; hydrous magnesium calcium silicate; hydrous 
magnesium silicate; Imperial; Luzenac Pharma; magnesium hydrogen 
metasilicate; Magsil Osmanthus; Magsil Star; powdered talc; purified French 
chalk; Purtalc; soapstone; steatite; Superiore; talcum. 
 
Empirical Formula and Molecular Weight: 
 Talc is a purified, hydrated, magnesium silicate, approximating to the 
formula Mg6 (Si2O5)4(OH) 4. It may contain small, variable amounts of 
aluminium silicate and iron. 
 
Functional Category: 
 Anti caking agent; glidant; tablet and capsule diluent; tablet and 
capsule lubricant. 
 
Pharmaceutical Applications: 
  Talc was once widely used in oral solid dosage formulations as a 
lubricant and diluents. However, it is widely used as a dissolution retardant in 
the development of controlled-release products. Talc is also used as a lubricant 
in tablet formulations; in a novel powder coating for extended-release pellets; 
and as an adsorbent. In topical preparations, talc is used as a dusting powder, 
although it should not be used to dust surgical gloves. Talc is a natural material; 
it may therefore frequently contain microorganisms and should be sterilized 
when used as a dusting powder. Talc is additionally used to clarify liquids and is 
also used in cosmetics and food products, mainly for its lubricant properties. 
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Use Concentration (%) 
Dusting powder 90.0 – 99.0 
Glidant and tablet lubricant 1.0 – 10.0 
Tablet and capsule diluent 5.0 – 30.0 
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MAGNESIUM STEARATE 
Non-proprietary Names 
BP    : Magnesium stearate 
JP    :  Magnesium stearate 
PhEur    :  Magnesium stearate  
USP-NF   :  Magnesium stearate 
Synonyms: 
Dibasic magnesium stearate; magnesium distearate; magnesia stearas; 
magnesium octadecanoate; octadecanoic acid, magnesium salt; stearic acid, 
magnesium salt; Synpro 90. 
Empirical Formula and Molecular Weight:  
 C36H70MgO4 and 591.24 
The USP32–NF27 describes magnesium stearate as a compound of magnesium 
with a mixture of solid organic acids that consists chiefly of variable proportions of 
magnesium stearate and magnesium palmitate (C32H62MgO4). The PhEur 6.5 
describes magnesium stearate as a mixture of solid organic acids consisting mainly of 
variable proportions of magnesium stearate and magnesium palmitate obtained from 
sources of vegetable or animal origin. 
Structural Formula  : [CH3 (CH2)16COO]2 Mg 
Functional Category  : Tablet and capsule lubricant. 
Pharmaceutical Applications 
Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical 
formulations. It is primarily used as a lubricant in capsule and tablet manufacture at 
concentrations between 0.25% and 5.0% w/w. It is also used in barrier creams.       
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8. METHODOLOGY 
Materials and Methods 
Table 2: Source of Gums 
SL 
NO 
POLYMER 
ISOLATED 
FROM 
BOTANICAL 
NAME 
FAMILY 
1 
Cassia 
roxburghii 
Seed Cassia roxburghii Caesalpiniaceae 
2 Tamarind gum Seed 
Tamarindus 
indica 
Leguminosae 
3 Neem gum Bark 
Azaridachta 
indica 
Meliaceae 
4 Tapioca starch Tubers 
Manihot 
esculenta 
Aspargaceae 
 
ISOLATION OF POLYMERS FROM THEIR RESPECTIVE SOURCES: 
Isolation of Cassia roxburghii Gum9 
 The seeds are collected and are dried at room temperature and are powdered 
using a grinder. A specific quantity of the seeds was weighed and is soaked in boiling 
water for 30 minutes, with occasional stirring. It is allowed to stand overnight and is 
filtered using an eight fold muslin cloth. Acetone is added to precipitate the mucilage 
present in it. The obtained mass is then centrifuged at 1500 rotations per second in a 
cooling centrifuge. The gum is separated and dried in hot air oven at 60 degree 
Celsius. Then it is passed through sieve number 100. 
 
 Collection of seeds → Size reduction → Powdering → Soaking in water for 
one day → Extraction by filtration → Centrifugation → Gum was dried → Passed 
through sieve number 100  
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Fig.8: Cassia roxburghii powder 
 
Isolation of Tamarind Gum38 
 Tamarind gum is obtained from endosperm of the seeds of tamarind tree. The 
seeds are collected from the tree and are heated with sand for some period of time. 
This is done for removing the coat. Then it is hammer milled and is grinded with the 
help of the grinder. Then it is passed through sieve number 100.  
 
 Collection of seeds → Heating with sand → Coat removal → Hammer milling 
→ Grinding → Sieved using sieve number 100 
 
Fig.9: Tamarind powder 
 
Isolation of Neem Gum39 
 An incision is made in the bark of the neem tree and after a month the exudate 
is collected. Then the whole mass is collected and is hydrated in distilled water. This 
is done to remove extraneous materials present in the gum. The mass is taken and 
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dried in hot air oven at 60oC. The completely dried mass is passed through sieve 
number 100. 
 
 Exudate is collected → Hydrated in distilled water → Extraneous materials 
were removed → Dried and powdered → Passed through sieve number 100  
 
Fig.10: Neem powder 
Isolation of Tapioca Starch8 
 The tapioca tubers are collected. It is peeled, washed and cut into small pieces. 
It is soaked in water for one hour. This is done to remove the extraneous particle from 
the surface. The mass is milled in a grinder and is dried in a hot air oven, then passed 
through sieve no 100. 
 
 Collection of tapioca tubers → Peeled, washed and cut into small pieces → 
Soaked in water for one hour → Milled and dried → Sieved using mesh number 100 
 
 
Fig.11: Tapioca powder 
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Table 3: List of equipments used 
Sl 
No 
INSTRUMENTS SUPPLIER/ MANUFACTURER 
1 Single pan analytical balance Schimadzu 
2 Tablet punching machine Rimek 12, Ahmedabad 
3 Hardness tester Campbell electronics –Mumbai 
4 Roche  friabilator Campbell electronics –Mumbai 
5 Dissolution apparatus Campbell electronics –Mumbai 
6 Tap density apparatus Thermonik 
7 Vernier caliper Shreji 
8 UV spectrophotometer Schimadzu, Japan 
 
 
Table 4: List of excipients used and their function 
Table Deter Determination of λ max 
a. Stock solution of 1mg/ml of paliperidone was prepared by dissolving 100mg 
of drug in 100 ml of simulated gastric fluid (0.825M hydrochloric acid and 
0.2% sodium chloride). 
b. The stock solution was serially diluted to get solutions in the range of 2-
10µg/ml and λmax of the solution was found out by scanning the solution from 
200-400 nm using UV-VIS spectrometer. 
c. The λ max of the solution was found to be 237 nm. 
 
 
 
 
Sl 
No 
MATERIAL SUPPLIER/ 
MANUFACTURER 
CATEGORY 
1 Paliperidone Mylan laboratory,Hyderabad API 
2 HPMC Loba chemie, Mumbai Sustained- release 
polymer  
3 MCC Mitutiyo,india Diluent 
4 Mag. St. Parag Fine Organics,Mumbai Lubricant 
5 Talc CP  Kelco US Inc. USA Glidant 
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Determination of standard curve 
a. Stock solution of 1000μg/ml of paliperidone was prepared by dissolving 
100mg of drug in 100 ml of simulated gastric fluid. 
b. From this take 10 ml and make up to 100 ml using simulated gastric fluid. 
c. From the above solution take 10ml and dilute to 100 ml using simulated 
gastric fluid. 
d. The stock solution was serially diluted to get solutions in the range of 2- 
10μg/ml. 
e. The absorbance of the different diluted solutions was measured in a UV-VIS 
spectrophotometer at 237nm. 
f. Calibration curve was plotted by taking concentration of the solution in µg on 
X-axis and absorbance on Y-axis and correlation co-efficient “r” was 
calculated. 
 
COMPATIBILITY STUDIES40 
 IR spectra matching approach was used for detection of any possible chemical 
interaction between drug and polymer. A physical mixture of drug and polymer was 
prepared and mixed with the suitable quantity of potassium bromide. About 100mg of 
mixture was compressed to form a transparent pellet using a hydraulic press at 6 tons 
pressure .It was scanned from 4000 to 400 cm-1 in FTIR spectrometer. The IR 
spectrum of the physical mixture was compared with those of pure drug and polymers 
and matching was done to detect any appearance or disappearance of peaks. The IR 
spectrums of the sample and of the paliperidone working/reference standard in the 
range of 4000 cm-1 to 400 cm-1 were taken by preparing dispersion in dry potassium 
bromide under the same operational conditions mentioned above. 
 
PREFORMULATION STUDIES41,42 
 Prior to development of a new dosage form with a drug moiety, it is essential 
that certain fundamental physical and chemical properties of the drug candidate and 
excipients are determined. The preformulation parameters like bulk density, tapped 
density, compressibility index hausner ratios etc. were determined as per IP 
procedure. The procedures for various tests are given below: 
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Angle of repose 
 This is carried out to determine the flow property of the granules. It is 
determined by the funnel method. A funnel was kept vertically at a specified height 
and the funnel bottom was closed. 10 gm of sample powder was filled inside the 
funnel. Then funnel was opened to release the powder to form a smooth conical heap 
which just touches the tip of the funnel. From the powder cone, the radius of the heap 
(r) and the height of the heap (h) were measured. 
 
 The angle of repose is represented as “θ” and is calculated using the following 
equation: 
Tan θ = h/r 
θ = Tan -1 h/r 
Where 
h = Height of the pile 
r = Radius of the pile. 
 
Table 5: Flow properties and corresponding Angle of repose 
Flow property Angle of repose (Degrees) 
Excellent 25-30 
Good 31-35 
Fair 36-40 
Passable 41-45 
Poor 46-55 
Very poor 56-65 
Very, very poor >66 
 
BULK DENSITY 
A specific quantity of the granules are weighed and transferred into a 50 ml 
graduated measuring cylinder. The initial volume and final volume are noted. 
Bulk Density = Weight of Sample / Bulk Volume  
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TAPPED DENSITY 
A specific quantity of granules is weighed and transferred into a 50 ml 
graduated measuring cylinder and is placed in the tapped density apparatus and was 
operated for a specific number of taps. The final volume was noted. 
 
Tapped Density = Weight of Sample/ Tapped Volume  
 
CARR’S INDEX 
The Carr’s index of the powder was determined by using formula: 
Carr’s index (%) = [(TBD - LBD) × 100]/TBD  
        LBD = Loose Bulk Density 
TBD = Tapped Bulk Density 
 
Table 6: Standard Values for Carr’s Index: 
 
 
 
 
 
 
 
 
 
COMPRESSIBILITY  INDEX 
 The compressibility index is determined from the bulk volume and 
tap volume.  
% C.I = (Tapped density - Bulk density) / Tapped density X 100 
 
 
CARR’S INDEX     % TYPE OF FLOW 
5-15 Excellent 
12-18 Good 
18-23 Satisfactory 
23-35 Poor 
35-38 Very poor 
>40 Extremely poor 
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Table7: Scale of Flowability based on Compressibility Index 
Compressibility 
index (%) 
Flow character 
≤10  Excellent  
11-15 Good 
16-20 Fair  
21-25 Passable 
26-31 Poor 
32-37 Very poor 
>38 Very, very poor  
 
HAUSNER’S RATIO: 
Hausner’s ratio is the ratio of the initial volume of the powder mass to the final 
volume of the powder mass obtained after the specified number of tapping. 
Table 8: Scale of Flowability based on Hausner’s Ratio 
 
 
 
 
 
 
 
 
 
 
 
COMPRESSION OF PALIPERIDONE SUSTAINED RELEASE TABLET 
 Weigh accurately about 200 mg of the mixture blend and fed into the die of 
single punch tablet press and compressed at 1.5N compression force using 8mm 
concave punches. 
 
  
Hausner’s ratio Flow character 
1-1.11 Excellent 
1.12-1.18 Good 
1.19-1.25 Fair 
1.26-1.34 Passable 
1.35-1.45 Poor 
1.46-1.59 Very poor 
>1.60 Very, very poor 
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POST COMPRESSION PARAMETERS42 
Weight Variation 
 Weight variation test for the tablets was performed as per the IP procedure. 
Ten tablets were weighed individually and the average weight was determined. The 
individual weight of all the ten tablets was noted. The percentage deviation of the 
individual weights from the average weight was then calculated. Deviation should not 
exceed the values given in Table: 9 
Table 9: Percentage deviation allowed in weight variation: 
 
AVERAGE WEIGHT OF 
TABLET 
PERCENTAGE DEVIATION 
80 mg or less 10 
More than 80 mg but less than 250mg 7.5 
250 mg or more 5 
 
 
Tablet hardness: 
Tablet hardness has been defined as the force required for breaking a tablet in a 
diametric compression test. A tablet was placed between two anvils of the hardness 
tester, force was applied to the anvils, and the crushing strength that caused the tablet 
to break was recorded. 
 
Friability test: 
The friability of the tablets were measured in a friability apparatus (Roche 
Friaberator Camp-bell Electronics, Mumbai). Ten tablets were initially weighed 
(Winitial) and placed into the friabilator. The friabilator was operated at 25 rpm for 4 
minutes and then the tablets were dedusted and weighed (Wfinal). Percentage friability 
was calculated from the loss in weight as given in equation as below. The weight loss 
should not be more than 1%. Determination was made in triplicate. 
 
                                                               Winitial - Wfinal   X 100                                                            
                                   % Friability=         Winitial           
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Assay of tablet 
Ten tablets were randomly weighed and crushed. Calculated the average weight 
and taken the powder equivalent to 10 mg of paliperidone base in a 100 ml volumetric 
flask. Add few ml simulated gastric fluid and sonicated for 30 minute. Then volume 
made up to 100 ml with simulated gastric fluid. The 1mL of resultant solution diluted 
to 100mL with simulated gastric fluid and the absorbance was measured using UV 
spectrophotometer at 237nm. 
 
In-vitro dissolution study43 
Parameters: 
Instrument  :  USP XIX Dissolution rate test apparatus 
Type    : II Paddle 
Medium  : 500 ml simulated gastric fluid  
     (0.825M hydrochloric acid and 0.2% sodium  
     chloride) 
Temperature  : 37±0.5°C. 
RPM    : 50 
Testing time  : 24 h 
Time points  : 1, 2, 3, 4, 5, 6, 7, 8,9,24 
Amount withdrawn :  5 ml. 
λ max   :  237 nm. 
 
Release kinetic analysis44 
 To study the release kinetics, data obtained from in-vitro drug release studies 
were plotted in various kinetic models: zero order (Equation 8) as cumulative amount 
of drug released vs. time, first order (Equation 9) as log cumulative percentage of 
drug remaining vs. time, and Higuchi’s model (Equation 10) as cumulative percentage 
of drug released vs. square root of time. 
C = K0 t      
Where 
K0 : is the zero-order rate constant expressed in units of  
concentration/time 
T : is the time in hours. 
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 A graph of concentration vs. time would yield a straight line with a slope 
equal to K0 and intercept the origin of the axis. 
LogC = LogCo−kt/2:303       
Where 
C0 :  is the initial concentration of drug, 
K :  is the first order constant, and t is the time. 
Q = Kt1/2     
Where 
K : is the constant reflecting the design variables of the  
system 
t  : is the time in hours. 
 
Mechanism of Drug Release 
 To evaluate the mechanism of drug release from Paliperidone sustained 
release tablets, data of drug release were plotted in Zero Order Kinetic equation as log 
cumulative percentage of drug released vs. time, and the exponent n was calculated 
through the slope of the straight line. 
Mt-M∞ = Ktn   
Where 
 Mt/M∞ - is the fractional solute release, 
 t   - is the release time, 
 K  - is a kinetic constant characteristic of the drug/  
    polymer system, and n is an exponent that   
    characterizes the mechanism of release of   
    tracers. 
Stability Studies45 
The prepared formulations which showed best results in vitro was selected and 
kept for stability testing for a period of three months. The tablets were kept at 40± 
2°C/75%±5%RH in a stability chamber in packed condition. These samples were 
analyzed for color, hardness, assay, % moisture absorbed and in vitro drug release, at 
the end of first, second and third month. Further these results were compared with the 
initial results to evaluate the stability of product.  
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9. FORMULATION AND DEVELOPMENT 
Sustained release tablets of paliperidone were prepared by direct compression 
using different natural polymers like Cassia roxburghii, Tamarindus indica, 
Azadirachta indica, Manihot esculenta and comparing with a standard rate retardant 
polymer HPMC at three different concentrations of polymers (30%, 50% and 75%). 
 
 
Table 10: Preparation of sustained release tablets using different natural 
polymers 
  
 The ingredients in the table above were accurately weighed and passed 
through sieve #60, then magnesium stearate and talc was passed through sieve #80. 
Then the materials were blended except magnesium stearate and talc for 20 minutes in 
ascending order. Later the powder mixture was blended with magnesium stearate and 
talc for 5 minutes. 
 
 
 
  
Drug Polymers 
Polymer percentage 
(%) 
 
 
 
 
PALIPERIDONE 
 
 
 
 
 
HPMC 35,50,75 
Cassia roxburghii 
 
35,50,75 
Tamarindus indica 
 
35,50,75 
Azadirachta indica 
 
35,50,75 
Manihot esculenta 
 
35,50,75 
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Table 11: Formula for development of tablet 
FORMULA DRUG HPMC CR TI AI ME MCC  TALC Mg.St. 
F1 6 35%     120 2 2 
F2 6 50%     90 2 2 
F3 6 75%     40 2 2 
F4 6  35%    120 2 2 
F5 6  50%    90 2 2 
F6 6  75%    40 2 2 
F7 6   35%   120 2 2 
F8 6   50%   90 2 2 
F9 6   75%   40 2 2 
F10 6    35%  120 2 2 
F11 6    50%  90 2 2 
F12 6    75%  40 2 2 
F13 6     35% 120 2 2 
F14 6     50% 90 2 2 
F15 6     75% 40 2 2 
 
Various polymers have been evaluated based on post compression parameters 
and in vitro dissolution data of prepared tablets. The suitable polymer and its 
concentration has optimised from its  
 
 Process efficiency 
 Friability 
 Assay of drug loaded 
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10. RESULTS AND DISCUSSION 
 
Determination of λ max:  
The wavelength showing maximum absorbance (λ max) for paliperidone was 
determined by scanning the standard stock solution of the drug using UV visible 
spectrophotometer. The λ max was found to be 237nm for paliperidone which is in 
accordance with the data available in literature. 
Table 12: Calibration curve data for paliperidone 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.12: Caliberation Curve of Paliperidone 
 
Concentration (µg/ml) Absorbance 
0 0 
2 0.069 
4 0.114 
6 0.173 
8 0.228 
10 0.277 
R² = 0.9962
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Compatibility studies: 
IR spectra matching approach was used for detection of any possible chemical 
interaction between the drug and the polymer. The samples were prepared by pressed 
pellet technique. The IR spectra was determined using JASCO FT/IR-4100. The 
scanning range was between 500- 4000cm-1. The spectrum obtained was shown in 
figure. 
 
 
Fig. 13:IR Spectra of Paliperidone 
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Table 13: Characteristic peaks of Paliperidone 
 
S.No 
Peaks Characteristic functional group 
1 
3294 NH Stretching 
2 
1630 C=O 
3 
1534 C=N 
4 
2911,2853 CH2 Stretching 
5 
2961 CH3 assymetric stretching 
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Fig.14:IR spectra of Paliperidone + Azadirachta Indica before stability study 
and after stability study 
 
Results and Discussion 
 
Dept of Pharmaceutics, KMCH College of Pharmacy Page 62 
 
Discussion: 
The data given in the table  shows the characteristic peaks detected in the IR 
spectrum of pure  drug, Paliperidone. The spectra of the pure drug and the spectra of 
the drug mixed with polymer are compared for the presence or absence of 
characteristic peak. It was found that the spectra of the drug with polymer showed all 
the characteristic peak of Palipeidone suggesting that there is no compatibility 
problem between the drug and polymer. 
Preformulation studies 
The preformulation parameters like angle of repose, bulk density, tapped 
density and compressibility index and Hausner’s ratios were studied to evaluate the 
flowability and compressibility of the powder formulations. The bulk density and 
tapped density was found to be in the range of 0.421 to 0.683 gm/cm3 and 0.529 to 
0.899 gm/cm3   
The compressibility and hausner’s ratio were found to be 17.81% to 30.47% and 
1.17 to 1.43. This indicates the granules have good flow character and have good 
compression property. All the results are within the prescribed limits. 
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Preformulation Parameters 
Table 14: Results of Preformulation Studies 
 
Evaluation of Post Compression Parameters 
The tablets were evaluated for thickness, hardness, friability, average weight 
and assay. The thickness of the formulated tablets was found to be in the range of 
0.31mm to 0.41mm. Hardness and friability was found to be 3.5-6kg/cm2 and 0.046-
0.523% which indicates the tablet has adequate mechanical strength. Weight variation 
of the tablets was found to be within the specified limits. . The drug content of all the 
formulations ranged from 89.78-96.81% indicating the presence of an acceptable 
amount of drug in the formulations. 
 
FORMULATION 
CODE 
ANGLE 
OF 
REPOSE 
BULK 
DEDNSITY 
TAPPED 
DENSITY 
C I HAUSNERS 
RATIOS 
F1 28°16' 0.625 0.899 30.47 1.43 
F2 30° 23' 0.681 0.883 22.87 1.29 
F3 32° 11' 0.423 0.521 18.80 1.23 
F4 33° 13' 0.431 0.552 21.92 1.28 
F5 33° 61' 0.617 0.819 24.66 1.32 
F6 34° 07' 0.625 0.830 24.69 1.33 
F7 38° 12' 0.602 0.809 25.58 1.34 
F8 38° 73' 0.421 0.529 20.41 1.25 
F9 39° 05' 0.683 0.889 23.17 1.30 
F10 26° 18' 0.512 0.623 17.81 1.21 
F11 27° 07' 0.458 0.537 14.71 1.17 
F12 39° 16' 0.465 0.571 18.56 1.22 
F13 33° 33' 0.620 0.891 30.41 1.43 
F14 34° 17' 0.615 0.811 24.16 1.31 
F15 34° 23' 0.601 0.807 25.52 1.34 
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Post Compression Parameters 
Table 15: Results of Evaluation of Tablets 
 
In vitro Dissolution Study of Tablets 
 Paliperidone controlled release tablets were formulated using 5 different 
polymers such as HPMC, Cassia roxburghii, Tamarind seed powder, Neem gum, 
Tapioca starch  in the percentage of 35%, 50%, and 75%. A total of 15 formulations 
were made using these polymers by direct compression method and 24 hours 
dissolution studies were carried out. 
 
Effect of HPMC on Drug Release 
 Cumulative percentage drug release for the different concentration of HPMC 
(35%, 50%,75%) is given the table below. Formulation F1, F2, F3 containing the 
different concentrations of HPMC are taken. The F1 and F2 do not show the drug 
release up to the desired period of time. . In case of formulation F3 containing 
HPMC(75%) also showed prolonged release but could not prolong the release for 
desired time.  
Formulation 
code 
Thickness 
(mm) 
Hardness 
(kg/cm2) 
Friability 
(%) 
Average 
wt(mg) 
Assay (%) 
F1 0.31 4.0 0.523 199 95.12 
F2 0.35 5.5 0.420 209 94.87 
F3 0.41 6.0 0.413 203 95.02 
F4 0.36 3.5 0.141 194 93.12 
F5 0.39 5.0 0.159 198 92.09 
F6 0.37 5.5 0.261 212 92.68 
F7 0.40 4.5 0.102 200 90.12 
F8 0.35 5.0 0.124 207 89.78 
F9 0.39 6.0 0.198 203 90.03 
F10 0.38 4.5 0.046 209 95.71 
F11 0.35 5.5 0.047 201 96.29 
F12 0.34 6.0 0.062 207 96.81 
F13 0.41 3.5 0.212 208 94.71 
F14 0.40 4.5 0.314 207 94.13 
F15 0.36 5.0 0.282 209 95.11 
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Table 16:  In vitro Release Data of F1, F2 and F3 
 
 
 
 
 
 
 
 
 
      
              Fig.15: Dissolution graph of HPMC (F1,F2,F3) 
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TIME F1 F2 F3 
0 0 0 0 
1 6.6 4.12 4.30 
2 31.12 30.75 8.71 
3 52.01 35.20 17.51 
4 58.07 40.12 26.51 
5 70.98 57.10 31.10 
6 81.12 68.01 35.81 
7 85.88 70.33 49.40 
8 87.27 77.60 52.09 
9 91.95 86.32 60.15 
24 95.60 95.96 96.50 
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Effect of Cassia roxburghii on Drug Release 
Cumulative percentage drug release for the different concentration of Cassia 
roxburghii (35%, 50% and 75%) is given the table below. These formulations were 
able to extend and control their release pattern to desired period of time. The drug 
release rate was found to be decreased when concentration of  polymers was 
increased. This may be due to increased swelling of the polymer when concentration 
is increased which leads to increased viscosity of the medium and thus increases the 
mean diffusional path length of the drug molecule to get released into the diffusion 
medium. 
Table 17:  In vitro Release Data of F4, F5 andF6 
 
 
 
 
 
 
 
 
 
 
TIME F4 F5 F6 
0 0 0 0 
1 8.76 7.16 7.06 
2 13.22 11.04 11.08 
3 19.94 15.55 16.34 
4 26.72 22.42 20.38 
5 35.76 24.71 23.76 
6 41.71 35.87 34.84 
7 56.32 42.80 50.10 
8 59.63 58.60 58.18 
9 65.60 63.59 62.50 
24 95.14 95.31 94.30 
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               Fig.16: Dissolution graph of Cassia roxburghii (F4,F5,F6) 
Effect of Tamarindus indica on drug release 
 Cumulative percentage drug release for the different concentration of 
Tamarindus indica(35%,50%,75%) is given the table below. The decrease in drug 
release rate as the concentration of the polymer increases may be attributed to the   
presence of a highly water soluble compound. It is seen that there is a faster rate of 
polymer swelling and a large increase in gel thickness to prevent immediate tablet 
disintegration, and thus controlling the diffusion of the drug. 
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Table 18: In vitro release data of F7, F8, F9 
 
 
 
 
 
 
 
 
 
 
Fig.17: Dissolution graph of Tamarindus indica (F7,F8, F9) 
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TIME F7 F8 F9 
0 0 0 0 
1 4.30 4.58 5.62 
2 29.76 6.65 7.63 
3 34.35 17.31 14.27 
4 41.20 27.83 19.98 
5 57.13 34.51 21.38 
6 66.47 39.20 25.98 
7 70.34 52.94 30.41 
8 77.10 59.84 31.95 
9 83.17 70.41 49.13 
24 94.12 95.20 96.27 
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Effect of Azadirachta indica on drug release 
 Cumulative percentage drug release for the different concentration of 
Azadirachta indica (35%,50%,75%) is given the table below. For formulation F12 
containing 75% polymer the cumulative release was found to be 36.02% in 9 hr and 
97.80% at 24 hours. The increase in polymer content delays the drug release as the 
polymer is hydrophilic and swellable polymer which produces increased swelling 
with increase polymer which might have increased diffusional path length for the drug 
to get diffuse across the membrane. 
 
Table 19:  In vitro release data of F10, F11, F12 
 
              
 
 
 
 
TIME F10 F11 F12 
0 0 0 0 
1 2.01 2.20 2.15 
2 4.40 4.41 4.41 
3 4.39 13.23 4.45 
4 6.62 15.55 8.89 
5 13.21 17.90 11.16 
6 24.11 22.45 13.46 
7 26.90 27.49 22.38 
8 29.28 29.52 26.98 
9 33.10 34.24 36.02 
24 96.97 98.14 97.80 
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Fig.18: Dissolution graph of Azadirachta indica (F10,F11,F12) 
 
Effect of Manihot esculenta on drug release 
 Cumulative percentage drug release for the different concentration of Manihot 
Esculenta (35%,50%,75%) is given the table below. In vitro dissolution data showed 
that these are not the best candidate for once daily dosage form as the release of the 
drug is not up to the desired extent. After  24 hours, the release of the drug was found 
to be 94-95% only. As a result, these formulations cannot be considered as optimized 
formulation.   
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Table 20:  In vitro release data of F13,F14,F15 
 
 
 
 
 
 
 
 
 
 
Fig.19: Dissolution graph of Manihot esculenta (F13,F14,F15) 
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TIME F13 F14 F15 
0 0 0 0 
1 2.19 2.10 2.09 
2 4.40 6.60 5.30 
3 8.83 6.84 5.31 
4 13.41 11.30 10.18 
5 20.08 20.03 19.70 
6 26.87 24.98 24.44 
7 42.43 39.31 26.87 
8 56.81 50.89 41.30 
9 71.98 66.30 48.23 
24 95.13 95.79 94.18 
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 From the in vitro dissolution data of the 15 formulations, almost all the 
formulations have the release up to the extended period of time. From these 
formulations F12 was chosen as the optimised formulation because of their extent 
their release up to 24 hours. All other post compression parameters like bulk density, 
tapped density, angle of repose, compressibility index and hausner's ratio are up to the 
specified limits. 
Dissolution profile of optimized formulation 
 From the dissolution data and from the post compression parameters it is 
concluded that Azadirachta indica 75% was fond to be the optimised formulation.   
Table 21:  In vitro release data of optimised formulation 
 
 
 
 
 
             
 
 
 
 
TIME FORMULATION F12 
0 0 
1 2.15 
2 4.41 
3 4.45 
4 8.89 
5 11.16 
6 13.46 
7 22.38 
8 26.98 
9 36.02 
24 97.8 
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Fig.20: Dissolution graph of optimised formulation(F12) 
Drug Release Kinetics analysis: 
The in-vitro drug release data of the optimized formulation was subjected to 
kinetic analysis by plotting various kinetic equations like zero order, first order and 
Higuchi plot.  The kinetic analysis data  of the formulation was shown in the table. 
The kinetic model that best fits with the release data of formulation was evaluated by 
the correlation coefficient (R2) values. According to the values obtained higher 
linearity was observed with linear plot(zero order) with R2 value of  0.955. Thus the 
formulation may follow zero order drug release. 
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Fig.21:Zero order plot 
 
 
Fig 22:First order plot 
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Fig 23: Higuichi plot 
Table 22: Result of kinetic analysis 
 
Mechanism of drug release 
Mechanism of drug release data can be assissed by plotting the drug release 
data in linear, exponential and power equations. From the regression coefficiant value, 
it may follow zero order kinetics. 
Stability study 
Here the tablets were loaded at accelerated condition at 400C±20C/75% 
RH±5% in a stability chamber. Samples were withdrawn at 30th and 60thday and 
evaluated for the physical appearance, drug content and dissolution characteristics. 
The stability analysis data were given in table above. The result showed that storage 
at 40 ºC had no effect on the hardness, disintegration time and dissolution time. 
y = 0.203x - 0.245
R² = 0.769
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FORMULATION Zero order 
(R
2
) 
First order 
(R
2
) 
Higuchi kinetics 
(R
2
) 
F 12 0.955 0.913 0.769 
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Table23: Stability study of formulation F12(Paliperidone+Neem gum 75%) 
SL. NO. PARAMETERS INITIAL 30th  DAY 60th  DAY 90th DAY 
1 
Physical 
appearance 
Grey Grey Grey Grey 
2 
Drug 
contenet(%) 
96.81% 96.75% 96.34% 96.05% 
3 
Dissolution 
(%CR in 24thhr) 
97.80% 97.38% 97.06% 96.92% 
 
 
 
SEM IMAGE OF Azadirachta Indica 
 
Fig24: SEM image of Azadirachta indica 
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11. SUMMARY 
The Paliperidone has various side effects which may be related to high blood 
plasma concentration levels excluding its use as a single immediate release dose. 
Presently Paliperidone is available as INVEGA that utilizes OROS technology which 
has several disadvantages. Hence present study was aimed to formulate sustained 
release tablet of paliperidone by direct compression method. 
 
Compatibility studies: 
IR spectra matching approach was used for detection of any possible chemical 
interaction between the drug and the polymer. The samples were prepared by pressed 
pellet technique. The IR spectra were determined using JASCO FT/IR-4100. 
Scanning range was between 500- 4000cm-1. FT-IR study revealed the absence of any 
chemical interaction between drug and polymer used. 
Pre-compression analysis: 
Preformulation studies of the sustained release and immediate release layer 
powder blend were done. The results of the evaluation suggests that all the granules 
exhibit good flow properties, so all the formulations were directly compressed to 
tablets.  
Post formulation studies of Tablets 
Tablets were evaluated for their physical parameters like hardness, thickness, 
friability, weight variation, and drug content uniformity complies with IP standards. 
 
In-vitro dissolution studies: 
The in-vitro drug release studies were performed using USP type 2 paddle type 
dissolution apparatus using simulated gastric fluid (0.825M hydrochloric acid and 
0.2% sodium chloride) for 24 hours. The formulation F12 (Azadirachta indica 75%) 
showed the maximum release of drug (97.8 %) at 24th hour. From the release data it is 
clear that the best sustaining ability was revealed by the formulation F12. 
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Drug Release Kinetics Analysis: 
The in-vitro drug release data of the optimized formulation was subjected to 
kinetic analysis by plotting various kinetic equations like zero order, first order and 
Higuchi plot. According to the values obtained higher linearity was observed with 
Higuchi plot, indicates drug is released by diffusion. The kinetic model that best fits 
with the release data of formulation was evaluated by the correlation coefficient (R2) 
values. According to the values obtained higher linearity was observed with linear 
plot (zero order) with R2 value of  0.955. Thus the formulation may follow zero order 
drug release. 
Stability studies: 
The tablets were loaded at accelerated condition at 400C±20C/75% RH±5% in 
a stability chamber. Samples were withdrawn at 30th , 60th and 90th day and evaluated 
for the physical appearance, drug content and dissolution characteristics. The result 
obtained from the study reveals that storage at 40 ºC had no effect on the hardness, 
disintegration time and dissolution time. The stability studies indicate that the 
sustained release tablet was suitable for drug delivery of paliperidone without having 
any physical stability issues. 
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12. CONCLUSION 
 
The formulation F12, 75% of Azadirachta indica could give rise to tablets 
exhibiting sustained drug release. Recent developments in the area of natural gums as 
excipients in the sustained release of drugs are to be explored and our research work 
provided the ground work for further studies in zero order release mechanisms.  
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INTRODUCTION
 Sustained release tablets and capsules are commonly
taken only once daily, compared with counterpart
conventional forms that may have to be taken three or
four times daily to achieve the same therapeutic effect.
 Binders are agents that are added either in dry form or in
wet form during wet granulation to form granules or to
provide cohesive impacts for directly compressed tablets.
 Natural binders provides the tablet formulations with
good hardness and friability. These binders prolongs the
dissolution rate of some slightly soluble drugs and can be
chosen as good candidate for sustained release.
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 Paliperidone is a prescription drug used for the treatment
of schizophrenia.
 The natural polymers were collected from the following
sources:
a. Cassia roxburghii seed
b. Tamarindus indica seed
c. Azadirachta indica bark
d. Manihot esculenta root tubers
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AIM  AND  OBJECTIVE
 The aim of this investigation is to formulate and evaluate
paliperidone sustained release tablets using natural
polymers and to compare with standard rate retardant
polymer HPMC.
Objective:
 To estimate the binding capacity of various natural gums
in granules and tablet formulations as a release retardant.
 To collect and isolate gums from different natural sources.
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 To prepare granules by direct compression method and
determine their physical properties.
 To optimise the binder concentration using appropriate
experimental design.
 To prepare and compress paliperidone tablets and compare
with standard rate retardant polymer, HPMC.
 To evaluate the invitro release principle of sustained release
paliperidone tablets.
 To perform the stability study on optimised paliperidone
formulation.
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LITERATURE REVIEW
Sl No Author’s 
Name
Journal Name Objective Conclusion
1
2
Mughal et al
Prajapati SK 
et al
AAPS 
PharmSci Tech. 
2011 
Formulation 
and evaluation 
of once daily 
sustained 
release tablets 
of aceclofenac
using natural 
gums
Developed  propranolol
hydrochloride-loaded 
matrix tablets using 
guargum and xantham
gum
Formulated once daily 
sustained release tablets 
of aceclofenac with 
natural polymers like 
xanthum gum and  
karaya gum  in different 
ratios.
Polymers can be used to 
formulate successful 
sustained release 
propranolol
hydrochloride matrix 
tablets that have 
desirable characteristics.
These polymers can be 
used in formulating 
succesful sustained 
release formulations. 
Xanthum gum has high 
sustained effect on the 
release of aceclofenac
than karaya gum.
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Sl
No
Author’s 
Name
Journal Name Objective Conclusion
3
4
Hiremath et al
Patel 
Shailendra et al
Int J Pharm. 
2008 
Natural Binding 
Agents in Tablet 
Formulation 
Developed sustained 
release tablet 
formulations of 
rifampicin and 
isoniazid combination 
using  HPMC and
HPC
Isolated Cassia
roxburghii, tamarind 
and tapioca from their 
respective sources and 
formulated diclofenac
tablets using these 
polymers.
They found out that 
controlled release  
formulations containing 
50% HPMC and 60%  
HPC, found to be of good 
quality and provided 
required release profile for 
both rifampicin and 
isoniazid.
Natural substances like 
starches, mucilages, gums 
and also dried fruits can be 
used as binding agent. 
They have been shown 
good potential as binding 
agent as well as they 
posses some other 
properties like 
disintegrating agent, fillers, 
sustain releasing agent.
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METHODOLOGY
ISOLATION OF NATURAL POLYMERS
1. ISOLATION FROM Cassia roxburghii
Collection of seed Size reduction powdering
Soaking in water for 1 day
Extraction through filtration
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2. ISOLATION FROM Tamarindus indica
Collection of seeds Heating with sand
Coat removalHammer milling
Grinding Sieving
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3.ISOLATION FROM Manihot esculenta
Collection of 
tapioca 
tubers
Peeled , washed 
and cut into 
small pieces
Sieved using 
mesh size 100 
Soaked in 
water for 1 
hour
Milled and dried
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4.ISOLATION FROM Azadirachta indica
Exudate is 
collected
Hydrated in 
distilled water
Extraneous 
materials 
were removed 
Passed through 
sieve 100 Dried and powdered
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FORMULATION AND DEVELOPMENT
Preparation of sustained release tablets using different   
natural polymer
Drug Polymers Polymer 
percentage(%)
PALIPERIDONE
HPMC 35,50,75
Cassia roxburghii 35,50,75
Tamarindus indica 35,50,75
Azadirachta indica 35,50,75
Manihot esculenta 35,50,75
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FORMULATION
FORMULA DRUG
(mg)
HPMC
(mg)
CR
(mg)
TI
(mg)
AI
(mg)
ME
(mg)
MCC
(mg) 
TALC
(mg)
Mg.St.
(mg)
F1 6 70 120 2 2
F2 6 100 90 2 2
F3 6 150 40 2 2
F4 6 70 120 2 2
F5 6 100 90 2 2
F6 6 150 40 2 2
F7 6 70 120 2 2
F8 6 100 90 2 2
F9 6 150 40 2 2
F10 6 70 120 2 2
F11 6 100 90 2 2
F12 6 150 40 2 2
F13 6 70 120 2 2
F14 6 100 90 2 2
F15 6 150 40 2 2
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RESULTS AND DISCUSSION
Determination of calibration curve:
Calibration curve of paliperidone at 237nm
Concentration 
(µg/ml)
Absorbance
0 0
2 0.069
4 0.114
6 0.173
8 0.228
10 0.277
R² = 0.9962
0
0.05
0.1
0.15
0.2
0.25
0.3
0 2 4 6 8 10 12
A
B
SO
R
B
A
N
C
E
CONCENTRATION
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Compatibility studies:
IR spectra matching approach was used for detection of any 
possible chemical interaction between the drug and the polymer.
IR Spectra of Paliperidone
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Interpretation of studied FTIR peaks with their characteristics 
functional groups
S.No
Peaks Characteristic functional group
1
3294 NH Stretching
2
1630 C=O
3
1534 C=N
4
2911,2853 CH2 Stretching
5
2961 CH3 asymmetric stretching
Discussion:
It was found that the spectra of the drug with polymer showed
all the characteristic peak of Paliperidone suggesting that there is
no compatibility problem between the drug and polymer.
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IR SPECTRA OF PALIPERIDONE+ Azadirachta indica
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Preformulation Study:
FORMULATION 
CODE
ANGLE 
OF 
REPOSE
BULK 
DEDNSITY
(g/ml)
TAPPED 
DENSITY
(g/ml)
COMPRESSIBILITY
INDEX
(%)
HAUSNER’S 
RATIOS
VISCOSITY
( poise)
F1 28°16' 0.625 0.899 30.47 1.43 1.0025
F2 30° 23' 0.681 0.883 22.87 1.29 1.0452
F3 32° 11' 0.423 0.521 18.80 1.23 1.1131
F4 33° 13' 0.431 0.552 21.92 1.28 0.7348
F5 33° 61' 0.617 0.819 24.66 1.32 0.7954
F6 34° 07' 0.625 0.830 24.69 1.33 0.8312
F7 38° 12' 0.602 0.809 25.58 1.34 0.7832
F8 38° 73' 0.421 0.529 20.41 1.25 0.8284
F9 39° 05' 0.683 0.889 23.17 1.30 0.8928
F10 26° 18' 0.512 0.623 17.81 1.21 0.9978
F11 27° 07' 0.458 0.537 14.71 1.17 1.0326
F12 39° 16' 0.465 0.571 18.56 1.22 1.1032
F13 33° 33' 0.620 0.891 30.41 1.43 0.5236
F14 34° 17' 0.615 0.811 24.16 1.31 0.6914
F15 34° 23' 0.601 0.807 25.52 1.34 0.7322
Discussion:
The results of the evaluation suggests that all the granules exhibit the good flow
properties so the formulation blend was directly compressed to tablets
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Evaluation of tablets 
Formulation 
code
Thickness 
(mm)
Hardness
(kg/cm2)
Friability (%) Average 
wt(mg)
Assay (%)
F1 0.31 4.0 0.523 199 95.12
F2 0.35 5.5 0.420 209 94.87
F3 0.41 6.0 0.413 203 95.02
F4 0.36 3.5 0.141 194 93.12
F5 0.39 5.0 0.159 198 92.09
F6 0.37 5.5 0.261 212 92.68
F7 0.40 4.5 0.102 200 90.12
F8 0.35 5.0 0.124 207 89.78
F9 0.39 6.0 0.198 203 90.03
F10 0.38 4.5 0.046 209 95.71
F11 0.35 5.5 0.047 201 96.29
F12 0.34 6.0 0.062 207 96.81
F13 0.41 3.5 0.212 208 94.71
F14 0.40 4.5 0.314 207 94.13
F15 0.36 5.0 0.282 209 95.11
Discussions:
The weight, thickness, hardness, friability, drug content and disintegration were all in the 
acceptable limits
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In-vitro dissolution studies:
1. Using HPMC
TIME F1 F2 F3
0 0 0 0
1 6.6 4.12 4.30
2 31.12 30.75 8.71
3 52.01 35.20 17.51
4 58.07 40.12 26.51
5 70.98 57.10 31.10
6 81.12 68.01 35.81
7 85.88 70.33 49.40
8 87.27 77.60 52.09
9 91.95 86.32 60.15
24 95.60 95.96 96.50
0
20
40
60
80
100
120
0 1 2 3 4 5 6 7 8 9 24
F1
F2
F3
time
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2. Using Cassia roxburghii Gum
TIME F4 F5 F6
0 0 0 0
1 8.76 7.16 7.06
2 13.22 11.04 11.08
3 19.94 15.55 16.34
4 26.72 22.42 20.38
5 35.76 24.71 23.76
6 41.71 35.87 34.84
7 56.32 42.80 50.10
8 59.63 58.60 58.18
9 65.60 63.59 62.50
24 95.14 95.31 94.30
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3. Using Tamarindus indica Gum
TIME F7 F8 F9
0 0 0 0
1 4.30 4.58 5.62
2 29.76 6.65 7.63
3 34.35 17.31 14.27
4 41.20 27.83 19.98
5 57.13 34.51 21.38
6 66.47 39.20 25.98
7 70.34 52.94 30.41
8 77.10 59.84 31.95
9 83.17 70.41 49.13
24 94.12 95.20 96.27
0
20
40
60
80
100
120
0 5 10 15 20 25 30
%
C
R
TIME
F7
  F8
F9
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4. Using Azadirachta indica Gum
TIME F10 F11 F12
0 0 0 0
1 2.01 2.20 2.15
2 4.40 4.41 4.41
3 4.39 13.23 4.45
4 6.62 15.55 8.89
5 13.21 17.90 11.16
6 24.11 22.45 13.46
7 26.90 27.49 22.38
8 29.28 29.52 26.98
9 33.10 34.24 36.02
24 96.97 96.86 97.80
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5. Using Manihot esculenta Gum
TIME F13 F14 F15
0 0 0 0
1 2.19 2.10 2.09
2 4.40 6.60 5.30
3 8.83 6.84 5.31
4 13.41 11.30 10.18
5 20.08 20.03 19.70
6 26.87 24.98 24.44
7 42.43 39.31 26.87
8 56.81 50.89 41.30
9 71.98 66.30 48.23
24 95.13 95.79 94.18
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DISCUSSION
• All the fifteen formulations of paliperidone sustained release
tablets were subjected to in-vitro release studies. These studies
were carried out by using dissolution apparatus type II (paddle
type) and the dissolution medium used was simulated gastric
fluid (0.825M hydrochloric acid and 0.2% sodium hydroxide)
for 24 hrs.
•Dissolution profiles of all formulations were compared by
cumulative percentage drug release verses time. From
dissolution results it was confirmed that the formulation F12
(neem gum75%) is the optimized formulation.
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Dissolution Profile of the Optimised Formulation
TIME FORMULATION F12
0 0
1 2.15
2 4.41
3 4.45
4 8.89
5 11.16
6 13.46
7 22.38
8 26.98
9 36.02
24 97.8
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Drug Release Kinetic analysis:
FORMULATION 
CODE
ZERO ORDER  
(R2)
FIRST ORDER
(R2)
HIGUCHI 
KINETICS
(R2)
F1 0.853 0.993 0.890
F2 0.924 0.831 0.734
F3 0.905 0.864 0.891
F4 0.934 0.904 0.836
F5 0.813 0.914 0.901
F6 0.993 0.834 0.807
F7 0.961 0.845 0.834
F8 0.834 0.901 0.806
F9 0.981 0.864 0.901
Dept of Pharmaceutics 29
FORMULATION 
CODE
ZERO ORDER
(R2)
FIRST ORDER
(R2)
HIGUCHI 
KINETICS
(R2)
F10 0.986 0.780 0.926
F11 0.980 0.922 0.968
F12 0.955 0.711 0.940
F13 0.934 0.894 0.884
F14 0.983 0.914 0.861
F15 0.994 0.761 0.904
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The regression coefficient value for zero order equation was
found to be near to 1 revealing that the dissolution profile of the
samples may follow zero order kinetics.
Stability Studies:
The tablets were loaded at accelerated condition at
400C±20C/75% RH±5% in a stability chamber.
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SL. NO. PARAMETERS INITIAL 30th DAY 60th DAY 90th DAY
1 Physical 
appearance
Grey Grey Grey Grey
2 Drug content (%) 96.81% 96.75% 96.34% 96.05%
3 Dissolution
(%CR in 24th
hour)
97.80% 97.38% 97.06% 96.92%
CONCLUSION
•From the IR spectra it is clear that there is no interaction
between the drug and the gum
•Sustained release tablets of Paliperidone using natural polymers
were successfully prepared by direct compression method.
•From the dissolution data, formulation F12 (neem75%) has the
maximum release of the drug in 24 hours.
•The formulation F12 can be adopted for sustained release to
improve the patient compliance and better disease management.
•From drug release kinetics data, the formulation follows zero
order kinetics.
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